Prostate cancer screening: Navigating the controversy

Prostate Cancer Diagnosis: PSA, Biopsy and Beyond

Volumn , Issue , 2013, Pages 11-26

  Hilton, William M ^a   Thompson, Ian M ^a   Parekh, Dipen J ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887612249     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-62703-188-2_2     Document Type: Chapter

References (79)

1. Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Yin M, et al. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol. 2008;179(3):892-5. discussion 895.
3. Mariotto AB, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
4. Zhang Y, et al. Understanding prostate cancer spending growth among Medicare beneficiaries. Urology. 2011;77(2):326-31.
5. A.U. Association. Early detection of prostate cancer and use of transrectal ultrasound. In: American Urological Association 1992 policy statement book. Baltimore: LWW; 1992.
6. Mettlin C, et al. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43(1):42-6.
7. Schroder FH, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8.
8. Jhaveri FM, et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17(10):3167-72.
9. Nam RK, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010;183(3):963-8.
10. Childe C. The control of a scourge, or how cancer is curable. New York: E.P. Dutton; 1907.
11. Mettlin C, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol. 1994;152 (5 Pt 2):1737-40.
12. Catalona WJ, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151(5):1283-90.
13. Etzioni R, et al. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making. 2008;28(3):323-31.
14. Stamey TA, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16.
15. Jacobsen SJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostatespecific antigen testing. JAMA. 1995;274(18): 1445-9.
16. Ablin RJ, et al. Precipitating antigens of the normal human prostate. J Reprod Fertil. 1970;22(3):573-4.
17. Nadji M, et al. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer. 1981;48(5):1229-32.
18. Seamonds B, et al. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology. 1986;28(6):472-9.
19. Cooner WH, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143(6):1146-52. discussion 1152-4.
20. Catalona WJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156-61.
21. Brawer MK, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147(3 Pt 2):841-5.
22. Brawer MK, et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol. 1993;150(1):106-9.
23. Potosky AL, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548-52.
24. Thompson IM, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1): 66-70.
25. Punglia RS, et al. Effect of verification bias on screening for prostate cancer by measurement of prostatespecific antigen. N Engl J Med. 2003;349(4):335-42.
26. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299(17):926-30.
27. Carter HB, et al. Longitudinal evaluation of prostatespecific antigen levels in men with and without prostate disease. JAMA. 1992;267(16):2215-20.
28. Oesterling JE. Age-specific reference ranges for serum PSA. N Engl J Med. 1996;335(5):345-6.
29. Catalona WJ, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152(6 Pt 1):2037-42.
30. Carter HB, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 1992;52(12):3323-8.
31. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol. 1994;152(4):1163-7.
32. Carter HB, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology. 1995;45(4):591-6.
33. Carter HB, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006; 98(21):1521-7.
34. Zlotta AR, et al. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/ml. J Urol. 1998;160(6 Pt 1):2089-95.
35. Kang SH, et al. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases. Int J Urol. 2006; 13(7):910-4.
36. Jung K, et al. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol. 1998;159(5):1595-8.
37. Walz J, et al. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer. 2008;113(10):2695-703.
38. Mikolajczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med. 2003;52(2):86-91.
39. Catalona WJ, et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol. 2003;170(6 Pt 1):2181-5.
40. Thompson IM, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529-34.
41. Vickers AJ, et al. The relationship between prostatespecific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res. 2010;16(17):4374-81.
42. Draisma G, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101(6):374-83.
43. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostatespecific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325-9.
44. Finne P, et al. Lead-time in the European randomised study of screening for prostate cancer. Eur J Cancer. 2010;46(17):3102-8.
45. Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-24.
46. Thompson IM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter [see comment][erratum appears in N Engl J Med. 2004 Sep 30;351(14):1470]. N Engl J Med. 2004;350(22):2239-46.
47. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289(11):1414-20.
48. Thompson IM, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1): 66-70.
49. Roobol MJ, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2009;56(4):584-91.
50. Hugosson J, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-32.
51. Loeb S, et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol. 2011;29(4):464-7.
52. Nelen V, et al. Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6 year screening interval. Eur J Cancer. 2010;46(17):3090-4.
53. Andriole GL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9.
54. Efstathiou JA, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27(1):92-9.
55. Carlsson S, et al. The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Goteborg randomised populationbased prostate cancer screening trial. Eur J Cancer. 2011;47(4):545-53.
56. Bussemakers MJ, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975-9.
57. Marks LS, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69(3):532-5.
58. Deras IL, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179(4): 1587-92.
59. Aubin SM, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010;184(5):1947-52.
60. Nakanishi H, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179(5):1804-9. discussion 1809-10.
61. de la Taille A, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185(6):2119-25.
62. Vickers AJ, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European randomized study of prostate cancer screening in Goteborg, Sweden. BMC Med. 2008;6:19.
63. Benchikh A, et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European randomized study of prostate cancer screening, France. BMC Cancer. 2010;10:635.
64. Vickers A, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol. 2010;28(15):2493-8.
65. Getzenberg RH, et al. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res. 1991;51(24):6514-20.
66. Leman ES, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology. 2007;69(4): 714-20.
67. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-54.
68. Nakayama M, et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem. 2004;91(3):540-52.
69. Enokida H, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005;11(18):6582-8.
70. Kuzmin I, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002;62(12):3498-502.
71. Woodson K, et al. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics. 2006;1(4): 183-6.
72. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366-81.
73. Roupret M, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007;13(6):1720-5.
74. Perner S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66(17):8337-41.
75. Lilja H, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer. 2011;117(6):1210-9.
76. Gudmundsson J, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med. 2010;2(62):62ra92.
77. American Urological Association Web site. 2011. http://www.auanet.org/content/guidelines-and-qualitycare/ clinical-guidelines.cfm. Accessed 15 Aug 2011.
78. U.S. Preventive Services Task Force Web site. 2011. http://www.uspreventiveservicestaskforce.org/uspstf08/ prostate/prostaters.htm. Accessed 15 Aug 2011.
79. American Cancer Society Web site. 2011. http://www. cancer.org/Cancer/ProstateCancer/MoreInformation/ ProstateCancerEarlyDetection/prostate-cancer-earlydetection- acs-recommendations. Accessed 15 Aug 2011.